Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report

It is relatively rare to achieve a median progression-free survival (PFS) of 40 months with pemetrexed monotherapy maintenance, especially in patients with advanced and severe lung cancer. Here, we reported a case of advanced severe lung adenocarcinoma treated with pemetrexed monotherapy maintenance...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Weichao, Zhu, Minli, Wang, Ruijuan, Tong, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072206/
https://www.ncbi.nlm.nih.gov/pubmed/36206106
http://dx.doi.org/10.1097/CAD.0000000000001402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072206/
https://www.ncbi.nlm.nih.gov/pubmed/36206106
http://dx.doi.org/10.1097/CAD.0000000000001402

Ejemplares similares